Zobrazeno 1 - 10
of 444
pro vyhledávání: ''
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Publikováno v:
British Journal of Cancer
Background Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood. Methods UK Biobank was used. Hormone concentrations were measured in serum collected in 2006–2010, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d482614b3e60f0e3b3fcf0d952cf3d1b
https://ora.ox.ac.uk/objects/uuid:2298adb9-eb05-46ad-ae36-48abd7ac39d1
https://ora.ox.ac.uk/objects/uuid:2298adb9-eb05-46ad-ae36-48abd7ac39d1
Autor:
Masako Kataoka, Masakazu Toi, Kaori Togashi, Mami Iima, Akane Ohashi, Shotaro Kanao, Daniel Förnvik
Publikováno v:
European Radiology
To compare breast density measured on digital breast tomosynthesis (DBT) (BI-RADS-based breast composition and fully-automatic estimation) and magnetic resonance imaging (MRI) (BI-RADS amount of fibroglandular tissue), and to evaluate the diagnostic
Autor:
Lauren Lissner, Marisa O.D. Silva, Charlotta Rylander, Maarit A. Laaksonen, Elisabete Weiderpass
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Scientific Reports
Scientific Reports
There is a lack of tangible measures for directed public health action to halt the increase in weight and cancer. We estimated the fraction and preventable cases of all and major body fatness-related cancers attributable to 7-years weight gain (≥ 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eceb346315a3d49626abdc74a66840c5
https://hdl.handle.net/10037/23797
https://hdl.handle.net/10037/23797
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Autor:
Masako Sato, Hidetoshi Kawaguchi, Satoshi Morita, Makiko Mizutani, Yoshie Hasegawa, Ken-ichi Watanabe, Yasuaki Sagara, Fumikata Hara, Takashi Morimoto, Takahiro Nakayama, Norikazu Masuda, Mitsuya Itoh, Shoichiro Ohtani, Nobuki Matsunami, Kenji Higaki, Masato Takahashi, Tetsuhiro Yoshinami
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and
Autor:
Hisashi Motomura, Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Shuhei Tomita, Koji Takada, Masahiko Ohsawa, Katsuyuki Takahashi, Kosei Hirakawa, Masaichi Ohira, Tsutomu Takashima, Takaharu Hatano
Publikováno v:
British Journal of Cancer
Background Immune responses in a tumour microenvironment can be evaluated by analysing tumour-infiltrating lymphocyte (TIL) density; this has been verified in the clinical setting. Although there are many reports on TIL density in primary tumours, li
Autor:
Michael S. Toss, Emad A. Rakha, Chitra Joseph, Padmashree C.G. Rida, Andrew R. Green, Ian O. Ellis, Nigel P. Mongan, Mohammed A. Aleskandarany, Ibrahim Alshankyty, Mansour Alsaleem, Sasagu Kurozumi, Angela Ogden, Ritu Aneja
E-cadherin is a tumor suppressor gene in invasive lobular breast cancer. However, a proportion of high-grade ductal carcinoma shows reduced/loss of E-cadherin. In this study, we assessed the underlying mechanisms and molecular implications of E-cadhe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a4fd096ae4d5a4d6360edf9b34a9f20
https://clok.uclan.ac.uk/34530/1/34530.pdf
https://clok.uclan.ac.uk/34530/1/34530.pdf
Autor:
Chris Twelves, Matthew Guo, Larisa Reyderman, Ishtiaq Husain Zubairi, R. Morrison, Nicola Cresti, Claudio Savulsky, Alan Anthoney, Vladimir Semiglazov, Ruth Plummer, T.R. Jeffry Evans, Constanta Timcheva
Publikováno v:
British Journal of Cancer
Background: \ud Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.\ud \ud Methods: \ud In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bccd2276eddef510b3a7b2fcc67aa0
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
Autor:
Judy Garber, Clara Li, Kevin S. Hughes, Suzanne B. Coopey, Francisco Acevedo, Amy S. Colwell, Danielle Braun, Regina Barzilay, Adam Yala, Tari A. King, Barbara L. Smith, Anthony J. Guidi, Curtis L. Cetrulo, Rong Tang, V. Diego Armengol, Zhengyi Deng
Publikováno v:
Other repository
© 2018, Springer Science+Business Media, LLC, part of Springer Nature. Purpose: Mammoplasty removes random samples of breast tissue from asymptomatic women providing a unique method for evaluating background prevalence of breast pathology in normal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e84cacd853968a680255161596c752
https://hdl.handle.net/1721.1/134753
https://hdl.handle.net/1721.1/134753